AU2017378782A1 - Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment - Google Patents
Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment Download PDFInfo
- Publication number
- AU2017378782A1 AU2017378782A1 AU2017378782A AU2017378782A AU2017378782A1 AU 2017378782 A1 AU2017378782 A1 AU 2017378782A1 AU 2017378782 A AU2017378782 A AU 2017378782A AU 2017378782 A AU2017378782 A AU 2017378782A AU 2017378782 A1 AU2017378782 A1 AU 2017378782A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- group
- alkynyl
- alkenyl
- pct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 C*C(C)[n]1c(ncnc2N)c2nc1 Chemical compound C*C(C)[n]1c(ncnc2N)c2nc1 0.000 description 5
- LWLRPALZYJPXGM-LLRMHZBASA-N Nc1ncnc2c1nc[n]2[C@@H]([C@H]1F)O[C@H](COP(O)(O[C@H]2[C@H]([n]3nnc4c3N=C(N)NC4=O)O[C@H](CO3)[C@H]2F)=S)[C@H]1OP3(O)=S Chemical compound Nc1ncnc2c1nc[n]2[C@@H]([C@H]1F)O[C@H](COP(O)(O[C@H]2[C@H]([n]3nnc4c3N=C(N)NC4=O)O[C@H](CO3)[C@H]2F)=S)[C@H]1OP3(O)=S LWLRPALZYJPXGM-LLRMHZBASA-N 0.000 description 2
- GCYMWOAJJYRHSJ-LMFWTOFOSA-N Nc1ncnc2c1nn[n]2[C@@H]([C@H]1F)O[C@H](COP(O)(O[C@H]2[C@H]([n]3nnc4c3N=C(N)NC4=O)O[C@H](CO3)[C@H]2F)=S)[C@H]1OP3(O)=S Chemical compound Nc1ncnc2c1nn[n]2[C@@H]([C@H]1F)O[C@H](COP(O)(O[C@H]2[C@H]([n]3nnc4c3N=C(N)NC4=O)O[C@H](CO3)[C@H]2F)=S)[C@H]1OP3(O)=S GCYMWOAJJYRHSJ-LMFWTOFOSA-N 0.000 description 2
- QNNUPCRMIGNPPK-HFPQONSNSA-N C=C1NC(N)=Nc2c1nn[n]2[C@@H]([C@@H]1OP(O)(OC[C@H]([C@H]([C@@H]2F)OP(O)(OC3)=S)O[C@H]2[n]2c(ncnc4N)c4nc2)=S)O[C@H]3[C@H]1F Chemical compound C=C1NC(N)=Nc2c1nn[n]2[C@@H]([C@@H]1OP(O)(OC[C@H]([C@H]([C@@H]2F)OP(O)(OC3)=S)O[C@H]2[n]2c(ncnc4N)c4nc2)=S)O[C@H]3[C@H]1F QNNUPCRMIGNPPK-HFPQONSNSA-N 0.000 description 1
- ZUINUHBLMNTALB-UHFFFAOYSA-N CC(C)[n](cc1)c2c1c(N)ncn2 Chemical compound CC(C)[n](cc1)c2c1c(N)ncn2 ZUINUHBLMNTALB-UHFFFAOYSA-N 0.000 description 1
- MMVXHMIFFAGTTP-UHFFFAOYSA-N CC(C)[n]1c(N=C(N)NC2=O)c2nc1 Chemical compound CC(C)[n]1c(N=C(N)NC2=O)c2nc1 MMVXHMIFFAGTTP-UHFFFAOYSA-N 0.000 description 1
- GHLNFLBYBAMEHM-UHFFFAOYSA-N CC(C)[n]1c(N=CNC2=O)c2nc1 Chemical compound CC(C)[n]1c(N=CNC2=O)c2nc1 GHLNFLBYBAMEHM-UHFFFAOYSA-N 0.000 description 1
- PGXRGCRWNRYZMY-UHFFFAOYSA-N CC(C)[n]1nnc2c1N=C(N)NC2=O Chemical compound CC(C)[n]1nnc2c1N=C(N)NC2=O PGXRGCRWNRYZMY-UHFFFAOYSA-N 0.000 description 1
- HGCMOMJHOFKUQX-UHFFFAOYSA-N CC(C)[n]1nnc2c1ncnc2C Chemical compound CC(C)[n]1nnc2c1ncnc2C HGCMOMJHOFKUQX-UHFFFAOYSA-N 0.000 description 1
- JMQVBUBNEQOXFF-OYSIUPSZSA-N CC(CNC=N)[C@@]([C@@H]([C@@H](COP(O)(O[C@H]1[C@H]([n]2c(N=C(N)NC3=O)c3nc2)O[C@H](CO)[C@H]1O)=O)O)OP=O)(N)O Chemical compound CC(CNC=N)[C@@]([C@@H]([C@@H](COP(O)(O[C@H]1[C@H]([n]2c(N=C(N)NC3=O)c3nc2)O[C@H](CO)[C@H]1O)=O)O)OP=O)(N)O JMQVBUBNEQOXFF-OYSIUPSZSA-N 0.000 description 1
- SFPFRHORTKYSAB-UHFFFAOYSA-N CCOc1nc(N)nc2c1nc[n]2C(C)C Chemical compound CCOc1nc(N)nc2c1nc[n]2C(C)C SFPFRHORTKYSAB-UHFFFAOYSA-N 0.000 description 1
- ZGQYPKZSGDFLPK-KRYRIAQDSA-N CNN([C@@H]([C@H]1F)O[C@H](COP(O)(O[C@H]2[C@H]([n]3nnc4c3N=C(N)NC4=O)O[C@H](CO3)[C@@H]2F)=S)[C@H]1OP3(O)=S)c(ncnc1N)c1N Chemical compound CNN([C@@H]([C@H]1F)O[C@H](COP(O)(O[C@H]2[C@H]([n]3nnc4c3N=C(N)NC4=O)O[C@H](CO3)[C@@H]2F)=S)[C@H]1OP3(O)=S)c(ncnc1N)c1N ZGQYPKZSGDFLPK-KRYRIAQDSA-N 0.000 description 1
- XSAZJDWYRBKTQW-PPNHMGJISA-N COC(C/N=C\N)[C@@H]([C@@H]([C@@H](CO)O)O)OP(O)(OC[C@H]([C@H]([C@H]1O)OP(C)(O)=O)O[C@H]1[n]1c(ncnc2N)c2nc1)=O Chemical compound COC(C/N=C\N)[C@@H]([C@@H]([C@@H](CO)O)O)OP(O)(OC[C@H]([C@H]([C@H]1O)OP(C)(O)=O)O[C@H]1[n]1c(ncnc2N)c2nc1)=O XSAZJDWYRBKTQW-PPNHMGJISA-N 0.000 description 1
- VCLLFTGIWZPYOO-MWGLIPOGSA-N CO[C@H]1[C@H]([n]2c(ncnc3N)c3nc2)O[C@H](COP(O)(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)O[C@H](CO3)[C@H]2F)=O)[C@H]1OP3(C)=O Chemical compound CO[C@H]1[C@H]([n]2c(ncnc3N)c3nc2)O[C@H](COP(O)(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)O[C@H](CO3)[C@H]2F)=O)[C@H]1OP3(C)=O VCLLFTGIWZPYOO-MWGLIPOGSA-N 0.000 description 1
- GGJUGXUIOWPWPZ-NQZSBSGZSA-N CP(OCC(O[C@H](C1OP(OC2)(S)=O)[n]3c(N=C(N)NC4=O)c4nc3)=C1O)(OC(C1OC3)[C@]23O[C@H]1[n]1c(ncnc2N)c2nc1)=O Chemical compound CP(OCC(O[C@H](C1OP(OC2)(S)=O)[n]3c(N=C(N)NC4=O)c4nc3)=C1O)(OC(C1OC3)[C@]23O[C@H]1[n]1c(ncnc2N)c2nc1)=O GGJUGXUIOWPWPZ-NQZSBSGZSA-N 0.000 description 1
- NPNMKJSTJKKAQC-LHWPIJEESA-N CP(OC[C@H](C([C@H]1OP(O)(OC[C@H]2OC3C[n]4c5ncnc(N)c5nc4)=O)=C)O[C@H]1[n]1c(N=C(N)NC4=O)c4nc1)(O[C@H]2[C@H]3O)=O Chemical compound CP(OC[C@H](C([C@H]1OP(O)(OC[C@H]2OC3C[n]4c5ncnc(N)c5nc4)=O)=C)O[C@H]1[n]1c(N=C(N)NC4=O)c4nc1)(O[C@H]2[C@H]3O)=O NPNMKJSTJKKAQC-LHWPIJEESA-N 0.000 description 1
- YTEUVGAKROSNIV-UZFYAQMZSA-N CP(OC[C@H]([C@H]([C@H]1OP(OC[C@H]2O[C@H]3[n]4nnc5c(N)ncnc45)(S)=O)F)S[C@H]1[n]1c(N=C(N)NC4=O)c4nc1)(O[C@H]2[C@@H]3F)=O Chemical compound CP(OC[C@H]([C@H]([C@H]1OP(OC[C@H]2O[C@H]3[n]4nnc5c(N)ncnc45)(S)=O)F)S[C@H]1[n]1c(N=C(N)NC4=O)c4nc1)(O[C@H]2[C@@H]3F)=O YTEUVGAKROSNIV-UZFYAQMZSA-N 0.000 description 1
- ZKUGHEUHMCFCAR-AOIXNMRPSA-N C[C@@H]1[C@H]([n]2c(ncnc3N)c3nc2)O[C@H](COP(O)(O[C@H](C2)[C@H]([n]3c(N=C(N)NC4=O)c4nc3)O[C@@H]2CO2)=O)[C@H]1OP2(C)=O Chemical compound C[C@@H]1[C@H]([n]2c(ncnc3N)c3nc2)O[C@H](COP(O)(O[C@H](C2)[C@H]([n]3c(N=C(N)NC4=O)c4nc3)O[C@@H]2CO2)=O)[C@H]1OP2(C)=O ZKUGHEUHMCFCAR-AOIXNMRPSA-N 0.000 description 1
- UKPFYLSXQHQLHS-AKFQRIKFSA-N C[C@@](COP(O[C@H]1C(N2NNC3=C2N=C(N)NC3=O)O[C@H](CO2)[C@@H]1F)(S)=O)([C@H]([C@H]1OC)OP2(S)=O)O[C@H]1[n]1c2ncnc(N)c2nc1 Chemical compound C[C@@](COP(O[C@H]1C(N2NNC3=C2N=C(N)NC3=O)O[C@H](CO2)[C@@H]1F)(S)=O)([C@H]([C@H]1OC)OP2(S)=O)O[C@H]1[n]1c2ncnc(N)c2nc1 UKPFYLSXQHQLHS-AKFQRIKFSA-N 0.000 description 1
- MJRLDRWDIYZOQX-UHFFFAOYSA-O C[NH2+]N(C(C1OP(O)(OCC(C(C2)OP(O)(OC3)=S)OC2c2cnc4[n]2ncnc4N)=S)OC3C1F)C(N=C(N)NC1=O)=C1N Chemical compound C[NH2+]N(C(C1OP(O)(OCC(C(C2)OP(O)(OC3)=S)OC2c2cnc4[n]2ncnc4N)=S)OC3C1F)C(N=C(N)NC1=O)=C1N MJRLDRWDIYZOQX-UHFFFAOYSA-O 0.000 description 1
- BHHGXZXSPYWZRE-UHFFFAOYSA-N C[n]1nnc2c1ncnc2N Chemical compound C[n]1nnc2c1ncnc2N BHHGXZXSPYWZRE-UHFFFAOYSA-N 0.000 description 1
- SMPCNKPYFMZJMO-UHFFFAOYSA-N Cc1c(C)ncnc1N Chemical compound Cc1c(C)ncnc1N SMPCNKPYFMZJMO-UHFFFAOYSA-N 0.000 description 1
- URCIAUBYTDQDAV-FJVYQUBKSA-N NC(NC1=O)=Nc2c1nn[n]2[C@@H]([C@@H]1OP(OC[C@H]([C@H](C2)OP(OC3)(S)=O)O[C@H]2c2c4ncnc(N)[n]4nc2)(S)=O)O[C@H]3[C@@H]1F Chemical compound NC(NC1=O)=Nc2c1nn[n]2[C@@H]([C@@H]1OP(OC[C@H]([C@H](C2)OP(OC3)(S)=O)O[C@H]2c2c4ncnc(N)[n]4nc2)(S)=O)O[C@H]3[C@@H]1F URCIAUBYTDQDAV-FJVYQUBKSA-N 0.000 description 1
- DERFUEHUCLQCQG-UHFFFAOYSA-N Nc1c(cc[n]2C(C3F)OC(COP(O)(OC4C([n]5nnc6c5N=C(N)NC6=O)OC(CO)C4)=S)C3OP(O)=S)c2ncn1 Chemical compound Nc1c(cc[n]2C(C3F)OC(COP(O)(OC4C([n]5nnc6c5N=C(N)NC6=O)OC(CO)C4)=S)C3OP(O)=S)c2ncn1 DERFUEHUCLQCQG-UHFFFAOYSA-N 0.000 description 1
- JRFBTYPQASRREA-PBTLVTEVSA-N Nc1c(cc[n]2[C@@H](C3(F)F)O[C@H](COP(O)(O[C@H]4[C@H]([n]5nnc6c5N=C(N)NC6=O)O[C@H](CO5)[C@@H]4F)=S)[C@H]3OP5(O)=S)c2ncn1 Chemical compound Nc1c(cc[n]2[C@@H](C3(F)F)O[C@H](COP(O)(O[C@H]4[C@H]([n]5nnc6c5N=C(N)NC6=O)O[C@H](CO5)[C@@H]4F)=S)[C@H]3OP5(O)=S)c2ncn1 JRFBTYPQASRREA-PBTLVTEVSA-N 0.000 description 1
- WLVMRUDHXZOPBD-JIZKSHQRSA-N Nc1c2nc[n]([C@@](CO[C@@H]3COP(O[C@H]4[C@H]([n]5c(N=C(N)NC6=O)c6nc5)SC(CO5)[C@H]4F)(S)=O)([C@@H]3OP5(S)=O)F)c2ncn1 Chemical compound Nc1c2nc[n]([C@@](CO[C@@H]3COP(O[C@H]4[C@H]([n]5c(N=C(N)NC6=O)c6nc5)SC(CO5)[C@H]4F)(S)=O)([C@@H]3OP5(S)=O)F)c2ncn1 WLVMRUDHXZOPBD-JIZKSHQRSA-N 0.000 description 1
- WLVMRUDHXZOPBD-YEBQKKQISA-N Nc1c2nc[n]([C@@](CO[C@@H]3COP(O[C@H]4[C@H]([n]5c(N=C(N)NC6=O)c6nc5)S[C@H](CO5)[C@H]4F)(S)=O)([C@@H]3OP5(S)=O)F)c2ncn1 Chemical compound Nc1c2nc[n]([C@@](CO[C@@H]3COP(O[C@H]4[C@H]([n]5c(N=C(N)NC6=O)c6nc5)S[C@H](CO5)[C@H]4F)(S)=O)([C@@H]3OP5(S)=O)F)c2ncn1 WLVMRUDHXZOPBD-YEBQKKQISA-N 0.000 description 1
- HUCQEPGBSIWYNF-UHFFFAOYSA-N Nc1ncn[n]2c1ncc2C(C1)OC(COP(OC2C([n]3c(N=C(N)NC4=O)c4nc3)OC(CO)C2F)(S)=O)C1OP(S)=O Chemical compound Nc1ncn[n]2c1ncc2C(C1)OC(COP(OC2C([n]3c(N=C(N)NC4=O)c4nc3)OC(CO)C2F)(S)=O)C1OP(S)=O HUCQEPGBSIWYNF-UHFFFAOYSA-N 0.000 description 1
- SXGILLNVRUZVHT-FTIDQPCRSA-N Nc1ncn[n]2c1ncc2C(CO[C@@H]1COP(O[C@H]2[C@H]([n]3nnc4c3N=C(N)NC4=O)S[C@H](CO3)[C@H]2O)(S)=O)[C@@H]1OP3(S)=O Chemical compound Nc1ncn[n]2c1ncc2C(CO[C@@H]1COP(O[C@H]2[C@H]([n]3nnc4c3N=C(N)NC4=O)S[C@H](CO3)[C@H]2O)(S)=O)[C@@H]1OP3(S)=O SXGILLNVRUZVHT-FTIDQPCRSA-N 0.000 description 1
- XOGJQVQEDYYFKP-FFWCMUJFSA-N Nc1ncn[n]2c1ncc2[C@@H](C1)O[C@H](COP(O)(O[C@H](C2)[C@H]([n]3nnc4c3N=C(N)NC4=O)O[C@]2(CF)CO2)=S)[C@H]1OP2(O)=S Chemical compound Nc1ncn[n]2c1ncc2[C@@H](C1)O[C@H](COP(O)(O[C@H](C2)[C@H]([n]3nnc4c3N=C(N)NC4=O)O[C@]2(CF)CO2)=S)[C@H]1OP2(O)=S XOGJQVQEDYYFKP-FFWCMUJFSA-N 0.000 description 1
- WWVUPCQKICGCQI-DJSBELFFSA-N Nc1ncn[n]2c1ncc2[C@@H](C1)O[C@H](COP(O[C@H]2[C@H](N3NNC4=C3N=C(N)NC4=O)S[C@H](CO3)[C@H]2O)(S)=O)[C@H]1OP3(S)=O Chemical compound Nc1ncn[n]2c1ncc2[C@@H](C1)O[C@H](COP(O[C@H]2[C@H](N3NNC4=C3N=C(N)NC4=O)S[C@H](CO3)[C@H]2O)(S)=O)[C@H]1OP3(S)=O WWVUPCQKICGCQI-DJSBELFFSA-N 0.000 description 1
- COOAYOMVDDJZCP-UHFFFAOYSA-N Nc1ncnc2c1NNN2C(C1F)OC(COP(OC2C([n]3c(N=C(N)NC4=O)c4nc3)SC(CO3)C2F)(S)=O)C1OP3=O Chemical compound Nc1ncnc2c1NNN2C(C1F)OC(COP(OC2C([n]3c(N=C(N)NC4=O)c4nc3)SC(CO3)C2F)(S)=O)C1OP3=O COOAYOMVDDJZCP-UHFFFAOYSA-N 0.000 description 1
- LTZOLLWDBUKGFU-UHFFFAOYSA-N Nc1ncnc2c1cc[n]2C(C1O)OC(COP(OC(C2)C([n]3c(N=C(N)NC4=O)c4nc3)OC2CO2)(S)=O)C1O[P]2=O Chemical compound Nc1ncnc2c1cc[n]2C(C1O)OC(COP(OC(C2)C([n]3c(N=C(N)NC4=O)c4nc3)OC2CO2)(S)=O)C1O[P]2=O LTZOLLWDBUKGFU-UHFFFAOYSA-N 0.000 description 1
- VIQFEYGWWKNVAI-ZAYMVFTPSA-N Nc1ncnc2c1nc[n]2[C@@H]([C@@H]1OC2)O[C@]2(COP(O)(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)O[C@H](CO3)[C@@H]2F)=S)[C@H]1OP3(O)=S Chemical compound Nc1ncnc2c1nc[n]2[C@@H]([C@@H]1OC2)O[C@]2(COP(O)(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)O[C@H](CO3)[C@@H]2F)=S)[C@H]1OP3(O)=S VIQFEYGWWKNVAI-ZAYMVFTPSA-N 0.000 description 1
- AAOIOCAYCBHKDO-ZSPDONRVSA-N Nc1ncnc2c1nc[n]2[C@@H]([C@H]1F)O[C@H](COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)S[C@H](CO3)[C@H]2F)(S)=O)[C@H]1OP3(S)=O Chemical compound Nc1ncnc2c1nc[n]2[C@@H]([C@H]1F)O[C@H](COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)S[C@H](CO3)[C@H]2F)(S)=O)[C@H]1OP3(S)=O AAOIOCAYCBHKDO-ZSPDONRVSA-N 0.000 description 1
- WKKCLGHQYBNSDA-FXFCMSPMSA-N Nc1ncnc2c1nc[n]2[C@](CO[C@@H]1COP(O[C@@](CS[C@@H]2CO3)([C@@H]2F)[n]2c(N=C(N)NC4=O)c4nc2)(S)=O)([C@@H]1OP3(S)=O)F Chemical compound Nc1ncnc2c1nc[n]2[C@](CO[C@@H]1COP(O[C@@](CS[C@@H]2CO3)([C@@H]2F)[n]2c(N=C(N)NC4=O)c4nc2)(S)=O)([C@@H]1OP3(S)=O)F WKKCLGHQYBNSDA-FXFCMSPMSA-N 0.000 description 1
- BNYFULCCURVVSO-UHFFFAOYSA-N Nc1ncnc2c1nn[n]2C(C1F)OC(COP(OC2C([n]3c(N=C(N)NC4=O)c4nc3)SC(CO3)C2F)(S)=O)C1O[P]3=O Chemical compound Nc1ncnc2c1nn[n]2C(C1F)OC(COP(OC2C([n]3c(N=C(N)NC4=O)c4nc3)SC(CO3)C2F)(S)=O)C1O[P]3=O BNYFULCCURVVSO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436697P | 2016-12-20 | 2016-12-20 | |
| US62/436,697 | 2016-12-20 | ||
| PCT/US2017/066554 WO2018118664A1 (en) | 2016-12-20 | 2017-12-15 | Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017378782A1 true AU2017378782A1 (en) | 2019-07-04 |
Family
ID=62627212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017378782A Abandoned AU2017378782A1 (en) | 2016-12-20 | 2017-12-15 | Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20190328762A1 (https=) |
| EP (1) | EP3558358A4 (https=) |
| JP (1) | JP2020511420A (https=) |
| AU (1) | AU2017378782A1 (https=) |
| CA (1) | CA3047394A1 (https=) |
| RU (1) | RU2019122602A (https=) |
| WO (1) | WO2018118664A1 (https=) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| NZ746112A (en) | 2016-03-18 | 2023-01-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| IL264049B2 (en) | 2016-07-06 | 2023-11-01 | Sperovie Biosciences Inc | Compounds, preparations and methods for treating the disease |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| PE20210255A1 (es) | 2016-12-01 | 2021-02-10 | Takeda Pharmaceuticals Co | Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon) |
| US11021511B2 (en) * | 2017-01-27 | 2021-06-01 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| WO2019046511A1 (en) | 2017-08-31 | 2019-03-07 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE |
| US11584774B2 (en) | 2017-09-11 | 2023-02-21 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| EP3697801B1 (en) * | 2017-10-16 | 2024-11-20 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| KR20200098511A (ko) | 2017-11-10 | 2020-08-20 | 다케다 야쿠힌 고교 가부시키가이샤 | Sting 조절제 화합물, 및 제조 및 사용 방법 |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| WO2020014127A1 (en) | 2018-07-10 | 2020-01-16 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| JP2022512541A (ja) * | 2018-08-29 | 2022-02-07 | シャタック ラボ，インコーポレイテッド | Ｐｄ－１系キメラタンパク質を含む併用療法 |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2020092127A1 (en) | 2018-10-29 | 2020-05-07 | Venenum Biodesign, LLC | Novel sting agonists |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| WO2020089815A1 (en) * | 2018-10-31 | 2020-05-07 | Novartis Ag | Antibody conjugates comprising sting agonist |
| US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| WO2020227421A1 (en) | 2019-05-09 | 2020-11-12 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| WO2021007160A1 (en) * | 2019-07-05 | 2021-01-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| TW202116330A (zh) * | 2019-07-09 | 2021-05-01 | 日商武田藥品工業股份有限公司 | Sting 促效劑及檢查點抑制劑之投與 |
| CA3147890A1 (en) * | 2019-07-19 | 2021-01-28 | Immunesensor Therapeutics, Inc. | Antibody-sting agonist conjugates and their use in immunotherapy |
| JP2022545402A (ja) * | 2019-08-15 | 2022-10-27 | ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク | 腫瘍関連エキソソームの免疫抑制をブロックするホスファチジルセリン結合分子 |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| DK4037708T3 (da) | 2019-09-30 | 2024-09-30 | Gilead Sciences Inc | HBV-vacciner og fremgangsmåder til at behandle HBV |
| AU2020366354A1 (en) * | 2019-10-14 | 2022-03-17 | Immunesensor Therapeutics, Inc. | Methods of treating cancer with a sting agonist |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| TW202200136A (zh) | 2020-04-10 | 2022-01-01 | 日商小野藥品工業股份有限公司 | 癌治療方法 |
| MX2022014110A (es) | 2020-05-15 | 2023-01-30 | Immunesensor Therapeutics Inc | Tratamientos combinados de agonistas de sting con inhibidores de puntos de control inmunitario. |
| EP4192474B1 (en) | 2020-08-07 | 2025-09-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| JP2023545178A (ja) | 2020-10-14 | 2023-10-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｔｉｎｇアゴニストと、細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む複合体との組合せ |
| IL302390A (en) | 2020-11-09 | 2023-06-01 | Takeda Pharmaceuticals Co | Drug antibody conjugates |
| JP2023550740A (ja) * | 2020-11-18 | 2023-12-05 | 武田薬品工業株式会社 | Ｓｔｉｎｇアゴニスト、チェックポイント阻害剤、及び放射線の投与 |
| WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| CN113521303B (zh) * | 2021-07-07 | 2024-01-02 | 中山大学附属第一医院 | 一种共同负载pd-l1抗体和sting激动剂的纳米囊泡及其制备方法与应用 |
| JP2024526874A (ja) | 2021-07-23 | 2024-07-19 | イミューンセンサー セラピューティクス、インコーポレイテッド | サイトカインとのｓｔｉｎｇアゴニスト併用療法 |
| GB202304385D0 (en) | 2023-03-24 | 2023-05-10 | Prostate Cancer Res | Combinatorial IL-15 therapy |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| CN120757600B (zh) * | 2025-09-10 | 2025-11-11 | 天津法尔玛制药有限公司 | 环二核苷酸2′,3′-cG4′-MeAMP、制备方法及其在制备先天免疫激活剂中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20160080A1 (es) * | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| WO2015074145A1 (en) * | 2013-11-22 | 2015-05-28 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
| US10695426B2 (en) * | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
| KR102222186B1 (ko) * | 2015-08-13 | 2021-03-03 | 머크 샤프 앤드 돔 코포레이션 | Sting 효능제로서 시클릭 디-뉴클레오티드 화합물 |
| AU2017321609C1 (en) * | 2016-08-30 | 2023-11-09 | Dana-Farber Cancer Institute, Inc. | Drug delivery compositions and uses thereof |
-
2017
- 2017-12-15 AU AU2017378782A patent/AU2017378782A1/en not_active Abandoned
- 2017-12-15 US US16/472,025 patent/US20190328762A1/en not_active Abandoned
- 2017-12-15 CA CA3047394A patent/CA3047394A1/en not_active Abandoned
- 2017-12-15 JP JP2019533106A patent/JP2020511420A/ja not_active Withdrawn
- 2017-12-15 WO PCT/US2017/066554 patent/WO2018118664A1/en not_active Ceased
- 2017-12-15 EP EP17885367.7A patent/EP3558358A4/en not_active Withdrawn
- 2017-12-15 RU RU2019122602A patent/RU2019122602A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020511420A (ja) | 2020-04-16 |
| EP3558358A4 (en) | 2020-09-30 |
| RU2019122602A (ru) | 2021-01-22 |
| WO2018118664A1 (en) | 2018-06-28 |
| US20190328762A1 (en) | 2019-10-31 |
| RU2019122602A3 (https=) | 2021-03-31 |
| EP3558358A1 (en) | 2019-10-30 |
| CA3047394A1 (en) | 2018-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11312772B2 (en) | Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment | |
| AU2017378782A1 (en) | Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment | |
| US11285131B2 (en) | Benzo[b]thiophene STING agonists for cancer treatment | |
| JP6894952B2 (ja) | 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ | |
| AU2017378783A1 (en) | Cyclic dinucleotide sting agonists for cancer treatment | |
| KR102232153B1 (ko) | Pd-1 길항제와 디나시클립의 조합을 사용한 암의 치료 | |
| EP4735050A1 (en) | Combination therapies for the treatment of cancer | |
| US11052065B2 (en) | Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist | |
| AU2024311205A1 (en) | Treatment method and use of pharmaceutical combination containing conjugate | |
| WO2020033283A1 (en) | Compositions and methods for treating cancer with a combination of programmed death receptor (pd-1) antibodies and vicriviroc | |
| RU2771811C2 (ru) | БЕНЗО[b]ТИОФЕНОВЫЕ АГОНИСТЫ STING ДЛЯ ЛЕЧЕНИЯ РАКА | |
| TW202502382A (zh) | 治療組合及其用途和治療方法 | |
| US20250000994A1 (en) | Combination therapies for the treatment of non-small cell lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |